Compared side by side
Semaglutide vs amycretin: how they differ
The short answer
Semaglutide activates one receptor, GLP-1; amycretin, also from Novo Nordisk, is one peptide that switches on the GLP-1 receptor and the amylin receptors, so it adds fullness after meals to GLP-1’s appetite signal. Semaglutide is FDA-approved for type 2 diabetes and weight management, as Ozempic and Wegovy; amycretin has been in phase 3 since February 2026 and isn’t approved anywhere. In their own trials, semaglutide averaged about 15% weight loss at 68 weeks, and weekly amycretin shots took off about 22% at 20 mg and 24% at 60 mg over 36 weeks in a small phase 1b/2a trial.
Side by side
| Compared | Semaglutide | Amycretin |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Ozempic, Wegovy | Zenagamtide, NNC0487-0111, Amy |
| What it is | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. | One peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet. |
| How it works | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. | One peptide that switches on both the GLP-1 receptor and the amylin receptors (and the calcitonin receptor), so it carries the two signals CagriSema gives as two drugs. GLP-1 curbs appetite and slows the stomach; amylin adds fullness after meals. A fatty-acid side chain binds it to albumin in the blood, so a weekly shot lasts. Novo Nordisk is developing it as a weekly injection and as a daily tablet. Investigational, in phase 3 since February 2026. |
| Commonly reported | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. | In trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere. |
| Studied range | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. | Research range: 0.4–60 mg, starting dose 0.2 mg. Studied in research — not a recommendation. |
| How often | Weekly SubQ | Weekly |
| Half-life | ~1 week (FDA label) | ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. | Used continuously, once weekly, in its trials: up to 36 weeks so far, with doses stepped up every 4 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk | Nausea, vomiting, diarrhea, decreased appetite |
- Category
- SemaglutideMetabolic & GLP-1
- AmycretinMetabolic & GLP-1
- Also known as
- SemaglutideOzempic, Wegovy
- AmycretinZenagamtide, NNC0487-0111, Amy
- What it is
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- AmycretinOne peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet.
- How it works
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- AmycretinOne peptide that switches on both the GLP-1 receptor and the amylin receptors (and the calcitonin receptor), so it carries the two signals CagriSema gives as two drugs. GLP-1 curbs appetite and slows the stomach; amylin adds fullness after meals. A fatty-acid side chain binds it to albumin in the blood, so a weekly shot lasts. Novo Nordisk is developing it as a weekly injection and as a daily tablet. Investigational, in phase 3 since February 2026.
- Commonly reported
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- AmycretinIn trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere.
- Studied range
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- AmycretinResearch range: 0.4–60 mg, starting dose 0.2 mg. Studied in research — not a recommendation.
- How often
- SemaglutideWeekly SubQ
- AmycretinWeekly
- Half-life
- Semaglutide~1 week (FDA label)
- Amycretin~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026)
- Route
- SemaglutideSubQ injection
- AmycretinSubQ injection
- Typical run
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- AmycretinUsed continuously, once weekly, in its trials: up to 36 weeks so far, with doses stepped up every 4 weeks. No trial has tested stopping it.
- Evidence
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- AmycretinModerate: animal studies + some human data
- Common side effects
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
- AmycretinNausea, vomiting, diarrhea, decreased appetite
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Amycretin
- Day 1–28 A very low start
- Day 57–140 · 1.25 mg The lowest dose tested for weight
- Day 85–252 With type 2 diabetes
- Day 113–196 · 5 mg Five milligrams
- Day 169–252 · 20 mg Twenty milligrams
- Day 253+ A long-term medicine, not a course
Questions people ask
How long do semaglutide and amycretin last?
The half-life of semaglutide is ~1 week (FDA label). The half-life of amycretin is ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026).
How often are semaglutide and amycretin taken?
Semaglutide: weekly SubQ. Route: SubQ injection. Amycretin: weekly. Route: SubQ injection.
How are semaglutide and amycretin dosed in research?
The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for amycretin is 0.4–60 mg, with a 0.2 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of semaglutide and amycretin?
For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For amycretin: nausea, vomiting, diarrhea, decreased appetite.